Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma

Aspirin led to a median disease-free survival of 1.16 years vs 1.35 years with placebo in patients with colorectal cancer liver metastases.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.